Pfizer, Teva Settle Patent Litigation on Viagra - - BioPharm International

ADVERTISEMENT

Pfizer, Teva Settle Patent Litigation on Viagra



Pfizer has settled its litigation against Teva Pharmaceuticals USA Inc., relating to Pfizer’s patent covering the use of Pfizer's Viagra (sildenafil citrate) to treat erectile dysfunction in 25-, 50-, and 100-mg tablets. The patent expires in April 2020, including pediatric exclusivity.  As a result of the settlement, Teva will be allowed to launch a generic version of Viagra under a royalty-bearing license on Dec. 11, 2017, in the United States on December 11, 2017, or earlier under certain circumstances. Teva will pay Pfizer a royalty for a license to produce its generic version.  The terms of the settlement agreement are otherwise confidential.  Teva has received tentative approval from FDA for its generic version of Viagra.  

Sources: Pfizer and Teva Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here